SCDAA 46th Annual National Convention has ended

Create Your Own Event

SCDAA 46th Annual National Convention

Celebrating Diversity Within the Sickle Cell Community: Commitment, Innovation, Practice

LaTasha Lee, PhD, MPH

American Society of Hematology
Senior Manager, Partnership Engagement
Washington D.C. Metro Area

https://ashresearchcollaborative.org/

9:15am EDT

Opening Ceremony: Celebrating Diversity Within the Sickle Cell Community. Meet the New National Child Ambassador Constellation A

10:30am EDT

Plenary Session I Community Based Organization Highlights Constellation AB Treatment Demonstration Update Constellation A

11:00am EDT

Newborn Screening Grant Update Constellation A

11:30am EDT

PCORI Grant Update Constellation A

12:00pm EDT

Hemolytic Anemia in Sickle Cell Disease: What is it and Why Does it Matter? Constellation AB

1:15pm EDT

Developing My Healthcare Passport Frederick/Columbia

1:45pm EDT

Chronic Pain Constellation D

2:15pm EDT

Transplantation Updates Constellation D

2:45pm EDT

Chronic Organ Damage Frederick/Columbia

3:30pm EDT

PLENARY II Clinical Trial Update Constellation A

7:00pm EDT

Chairman's Reception and Generation S " Rock the Block Event " Piesces

9:30am EDT

Charles F. Whitten, MD Memorial Lecture Constellation A

12:00pm EDT

Finding your Voice between the Patient and Caregiver Baltimore/ Annapolis

1:30pm EDT

Lonzie Lee Jones Patient Advocacy Symposium Constellation A

3:15pm EDT

Effect Of Long Term Treatment With Sc411 On Sickle Cell Crisis Rate In Children With Sickle Cell Disease Constellation C Patient and Caregiver Perspectives on Areas of Burden In Sickle Cell Disease Management Baltimore/ Annapolis

3:30pm EDT

Compassionate-Use Voxelotor (GBT440) For Up To 2 Years In Patients With Severe Sickle Cell Disease And Life-Threatening Comorbidities Constellation C The Opioid Epidemic And CDC Guidelines: A Case Of An Unfortunate Consequences Paved By Good Intentions Constellation D

3:45pm EDT

Crizanlizumab 5.0 Mg/Kg Increased the Time to First On-Treatment Sickel Cell Pain Crisis (SCPC) and the Likelihood of not Experiencing SCPC While on Treatment: Subgroup Analyses of the Phase 2 Sustain Study Constellation C

4:00pm EDT

Parent and Youth Barriers to Hydroxyurea Adherence in Adolescents with Sickle Cell Disease Constellation C

4:30pm EDT

Crizanlizumab Treatment is Not Asoociated with the Development of Proteinuria and Hematuria in Patients with Sickle Cell Disease: Sustain Study Safety Analysis Constellation C

4:45pm EDT

Genome Editing to Fix the Sickle Cell Disease Causing Variant in Sickle Cell Patient Hematopoietic Stem Cells Constellation C

5:15pm EDT

The Clinical-Stage SGC Stimulator Olinciguat Prevents Increase Of Plasma Biomarkers Of Intravascular Inflammation And Suppresses Leukocyte-Endothelial Interactions In Tnfa-Treated Mice Constellation C

8:30am EDT

Pravastatin-Mediated Modulation Of Sickle Red Cell Adhesion Using Mouse Endothelial Cells In Vitro Constellation B

8:45am EDT

The Strong-SCD Trial: A Phase 2 Study Ofolinciguat (IW-1701), A Stimulator Of Soluble Guanylate Cyclase (sGC) Inpatients With Sickle Cell Disease (SCD) Constellation B

9:00am EDT

SC411 For Treatment Of Children With Sickle Cell Disease: A Phase 2, Randomized, Double-Blind, Dose-Finding, Placebo-Controlled, Parallel-Group, Multi-Center Study (Scot Trial) Constellation B

9:15am EDT

Clinical Development Of Rivipansel (GMI-1070) For The Treatment Of Acute Vaso-Occlusive Crisis In Sickle Cell Disease Constellation B

9:30am EDT

A Systematic Literature Review Of Patient-Reported Outcome Instruments Used In Sickle Cell Disease Constellation B

10:00am EDT

Gene Therapy for Sickle Cell Disease: Fact or Fiction? Constellation CD

10:30am EDT

Clarice D. Reid, MD Lecture – Global Strategies for Sickle Cell Disease Constellation CD

11:00am EDT

National Partner Updates Constellation CD